Studying CBD
No Result
View All Result
  • Home
  • CBD
  • About CBD
  • What is CBD
  • Home
  • CBD
  • About CBD
  • What is CBD
No Result
View All Result
Studying CBD
No Result
View All Result
Home CBD

Latest Round of FTC CBD Letter-Writing Campaign Has Anonymous Pen Pals

Peter F. by Peter F.
September 27, 2019
in CBD
38 1
0
New Concerns About Ads for E-Cigs and CBD
32
SHARES
359
VIEWS
Share on TwitterShare on Facebook

[ad_1]

Three companies get talking-to over CBD health claims

Ambitious!

Three unnamed companies were on the receiving end of firm but undoubtedly polite letters from the Federal Trade Commission warning them to take a long, hard look at their cannabidiol (CBD) advertising.

Using scare quotes designed to make them seem like dangerously unhip parents, the commission announced that the missives were sent to “three companies that sell oils, tinctures, capsules, ‘gummies,’ and creams containing cannabidiol (CBD), a chemical compound derived from the cannabis plant.”

Apparently the anonymous companies have been claiming that their CBD-related products cure or alleviate a variety of conditions, including (take a deep breath) cancer, Alzheimer’s disease, arthritis, multiple sclerosis, cigarette addiction, colitis, autism, anorexia, bipolar disorder, post-traumatic stress disorder, schizophrenia, anxiety, depression, autoimmune disorders, heart disease, Lou Gehrig’s disease (ALS), stroke, Parkinson’s disease, epilepsy, traumatic brain injuries, diabetes, Crohn’s disease, psoriasis, multiple sclerosis, fibromyalgia, AIDS, asthma, and, as one company allegedly claimed, “most major degenerative diseases.”

The commission asked that the three recipients gather the evidence needed to back up these and other claims, warning of potential action under the FTC Act should they fail to do so.

The Takeaway

These latest letters add just a little more torque to the slowly but steadily turning wheel of federal CBD-related activity we discussed back in April, inaugurated by a statement from then-FDA Commissioner Gottlieb and a joint letter-writing campaign between the Food and Drug Administration and the commission. FDA-sponsored hearings followed, along with yet more letters, but still – no bombshells regarding a comprehensive CBD regulatory stance.

RELATED  First CBD oil registry issued in Costa Rica | Dentons

We’re keeping our eyes open.

[ad_2]

Source link

Tweet8Share13Share3Share
Peter F.

Peter F.

We study the effects of cannabidiol (CBD), a non-psychoactive component of cannabis that does not produce the high associated with smoking or using it."There is a lot of debate on the health effects of marijuana and the use of cannabinoids, which are a group of compounds found in marijuana that have anti-inflammatory, pain-relieving, anti-nausea and anti-emetic properties. However, there is a lack of solid scientific evidence to guide us in the application of cannabis therapeutics."

No Result
View All Result
  • Privacy Policy
  • Contact
  • About us

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
We use cookies to personalize content and ads, to provide social media features and to analyze our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. You consent to our cookies if you continue to use our website.. For more information contact Info@sdmediagrp.comContinuePrivacy policy